Nuvectis Pharma, Inc.

For the period ended Dec 31, 2025. Filed Feb 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

NVCT$21.08+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2025 and 2024

BALANCE SHEETS


· · December 31,
· · 2025 · · 2024
Assets
CURRENT ASSETS · · · ·
Cash and cash equivalents	$31,634	$18,533
Other current assets	75	74
TOTAL CURRENT ASSETS	31,709	18,607

TOTAL ASSETS	$31,709	$18,607

Liabilities and Shareholders’ Equity

CURRENT LIABILITIES
Accounts payables	$6,274	$2,498
Accrued liabilities	115	840
Employee compensation and benefits	6,907	5,556
TOTAL CURRENT LIABILITIES	13,296	8,894
TOTAL LIABILITIES	13,296	8,894

COMMITMENTS AND CONTINGENCIES, see Note 3

SHAREHOLDERS’ EQUITY, see Note 6
Common Shares, $0.00001 par value – 60,000,000 shares authorized as of December 31, 2025, and December 31, 2024, 25,676,798, and 19,495,683 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	*	*
Additional paid in capital	118,100	82,958
Accumulated deficit	(99,687)	(73,245)
TOTAL SHAREHOLDERS’ EQUITY	18,413	9,713
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$31,709	$18,607

*Represent amount lower than $1,000 USD.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.